Sugi Predict

Sugi Predict / Targets / CTSC

CTSC

Dipeptidyl peptidase 1 · P53634 · CTSC on Sugi Atlas →

42,338 patent compounds predicted against CTSC, 23,764 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL289735 SCHEMBL289735 0.87 20/20
SCHEMBL289736 SCHEMBL289736 0.87 20/20
SCHEMBL289933 SCHEMBL289933 0.77 20/20
SCHEMBL289934 SCHEMBL289934 0.77 20/20
SCHEMBL290061 SCHEMBL290061 0.73 20/20
SCHEMBL289515 SCHEMBL289515 0.72 20/20
SCHEMBL289902 SCHEMBL289902 0.72 20/20
SCHEMBL288984 SCHEMBL288984 0.72 20/20
SCHEMBL289370 SCHEMBL289370 0.72 20/20
SCHEMBL289891 SCHEMBL289891 0.71 20/20
SCHEMBL289892 SCHEMBL289892 0.71 20/20
SCHEMBL289755 SCHEMBL289755 0.69 20/20
SCHEMBL299207 SCHEMBL299207 0.69 20/20
SCHEMBL289954 SCHEMBL289954 0.68 20/20
SCHEMBL289955 SCHEMBL289955 0.68 20/20
SCHEMBL289950 SCHEMBL289950 0.67 20/20
SCHEMBL290172 SCHEMBL290172 0.64 20/20
SCHEMBL289116 SCHEMBL289116 0.63 20/20
SCHEMBL289117 SCHEMBL289117 0.63 20/20
SCHEMBL289849 SCHEMBL289849 0.63 20/20

Clinical trials — most relevant to CTSC by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction in Diabetic Rats PHASE4COMPLETED
Effect of Sitagliptin and an ACE Inhibitor on Blood Pressure in Metabolic Syndrome PHASE4COMPLETED
Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes PHASE3COMPLETED
Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes PHASE3COMPLETED
Sitagliptin and Endothelial Dysfunction PHASE3UNKNOWN
Quantification of the Dipeptidyl Peptidase (DPP)-4 Inhibition-mediated Enhancement of the Activity of the Entero-insular Axis PHASE2/PHASE3COMPLETED
Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis PHASE3COMPLETED
Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients PHASE3ENROLLING_BY_INVITATION
Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus PHASE2COMPLETED
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus PHASE2COMPLETED
Comparative Clinical Study to Evaluate the Possible Efficacy and Safety of Oral N-Acetyl Cysteine Versus Rectal Diclofenac in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis PHASE1/PHASE2COMPLETED
Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients PHASE2COMPLETED
Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus PHASE1COMPLETED
The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism EARLY_PHASE1UNKNOWN
Respiratory Cathepsins, Proteases Inhibitors and Glycosaminoglycans (GAG) in Mucopolysaccharidosis nanCOMPLETED
Effect of Dipeptidyl Peptidase IV After Diets in näive Type 2 Diabetic Patients nanCOMPLETED
Acute Pancreatitis Targets (APT) Study nanCOMPLETED
The Incretin Effect in Patients With Kidney Impairment nanCOMPLETED
Nephron Sparing Renal Surgery and Total Nephrectomy nanCOMPLETED
Influence of DPP-4 on Inflammatory Parameters in Diabetics: Gender Aspects nanUNKNOWN
DPP4 Activity, Microvascular Reactivity and Inflammation nanCOMPLETED
The CHYMASE Angiotensin-(1-12) Axis in Cardiovascular Disease nanUNKNOWN
Evaluating ImmuNe Changes in the Evolution of Pre Type 1 Diabetes With Adult ONset nanCOMPLETED
Effect of Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From HIRA Database nanUNKNOWN
The Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and Inflammation nanUNKNOWN
Long-term Health After Severe Acute Malnutrition in Children and Adults: the Role of the Pancreas nanCOMPLETED
Progression of Coronary Atherosclerosis in Asymptomatic Diabetic Subjects nanUNKNOWN
Chemokine Mechanisms in Chronic Pelvic Pain nanCOMPLETED
Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure nanCOMPLETED
Cardiac Injury in COVID-19: a Pathology Study nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CTSC binder may also engage these)

ProteinNameSimilarity
P97821 — 1.000 P97821 →
Q5RB02 — 1.000 Q5RB02 →
Q3ZCJ8 — 1.000 Q3ZCJ8 →
Q60HG6 — 1.000 Q60HG6 →
P80067 — 1.000 P80067 →
O97578 — 0.999 O97578 →
Q26563 — 0.995 Q26563 →
Q94K85 — 0.993 Q94K85 →
P19092 — 0.993 P19092 →
P25802 — 0.992 P25802 →
Q8VCM7 — 0.991 Q8VCM7 →
P25793 — 0.990 P25793 →
B4F6N6 — 0.990 B4F6N6 →
A9QQ26 — 0.989 A9QQ26 →
Q93105 — 0.989 Q93105 →
Q9SUL1 — 0.989 Q9SUL1 →
O09046 — 0.989 O09046 →
A4KX75 — 0.988 A4KX75 →
Q9TST1 — 0.988 Q9TST1 →
Q5RFQ6 — 0.988 Q5RFQ6 →
G5EDW5 — 0.988 G5EDW5 →
Q9VN93 — 0.988 Q9VN93 →
P86785 — 0.988 P86785 →
Q8BH35 — 0.988 Q8BH35 →
E9Q6D8 — 0.988 E9Q6D8 →
A0A218QX58 — 0.988 A0A218QX58 →
LOXL2 Lysyl oxidase homolog 2 0.988 landscape →
P17634 — 0.987 P17634 →
Q93VC9 — 0.987 Q93VC9 →
Q90703 — 0.987 Q90703 →